ArticleHeliyon2024

Changes of circulating tumor cells expressing CD90 and EpCAM in early-phase of atezolizumab and bevacizumab for hepatocellular carcinoma.

Takuto Nosaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.